Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 2/20 | 0.32 |
| ▸ | CDC25B | P30305 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787032 | 1.00 | CDC25A (0.32) | CDC25ACDC25B | |
| SCHEMBL2610385 | 0.75 | — | — | |
| SCHEMBL2610383 | 0.73 | — | — | |
| SCHEMBL15009376 | 0.71 | — | — | |
| SCHEMBL25928669 | 0.69 | — | — | |
| SCHEMBL14552924 | 0.69 | — | — | |
| SCHEMBL18425007 | 0.67 | CDC25A (0.32) | CDC25ACDC25B | |
| SCHEMBL24768558 | 0.65 | — | — | |
| SCHEMBL14155256 | 0.65 | — | — | |
| SCHEMBL21789849 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3375770-B1 | CYCLOPROPANE COMPOUND | KAO CORP (JP) | 2020-06-03 | — | — | EP | disclosed |
| US-20190055179-A1 | CYCLOPROPANE COMPOUND | KAO CORPORATION (JP) | 2019-02-21 | — | — | US | disclosed |
| EP-3375770-A1 | CYCLOPROPANE COMPOUND | Kao Corporation (JP) | 2018-09-19 | — | — | EP | disclosed |
| US-8450533-B2 | Cyclopropanation process | GIVAUDAN SA (CH) | 2013-05-28 | — | — | US | disclosed |
| US-20110124924-A1 | Cyclopropanation Process | GIVAUDAN SA (CH) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055179-A1 | CYCLOPROPANE COMPOUND | CNR1, TRPA1, TRPV1 | CDC25A 2610/4885CDC25B 3165/4885 |
| US-20110124924-A1 | Cyclopropanation Process | CBR3, CYP4F3, DBF4 | CDC25A 3988/4885CDC25B 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.